# Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

> **NCT01925950** · PHASE2 · TERMINATED · sponsor: **Soligenix** · enrollment: 2 (actual)

## Conditions studied

- Chronic Gastrointestinal Graft vs Host Disease

## Interventions

- **DRUG:** orBec
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01925950
- **Lead sponsor:** Soligenix
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-12
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study was stopped due to patient enrollment challenges.
- **Last updated:** 2018-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01925950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01925950, "Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01925950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*